Significance and Impact of the Study: Manuka honey is known to have a broad spectrum of antimicrobial activity, with the bacterial cell wall being suggested as a predominant site of action. This study has demonstrated that Manuka honey has activity against Ureaplasma spp., a genus of cell wall-free bacteria which are intrinsically resistant to many available antibiotics making treatment inherently difficult. This is the first report of the antimicrobial activity of Manuka honey against a bacterial pathogen, in the absence of a cell well and opens scope for the use of components of Manuka honey as a therapeutic among Ureaplasma infections. 
Introduction
Ureaplasma spp. are a genus of bacteria of clinical relevance strongly linked with preterm birth and subsequent development of neonatal complications such as bronchopulmonary dysplasia, intraventricular haemorrhaging and necrotising enterocolitis (Viscardi 2014) . In addition, these pathogens are becoming recognized in sexual health (Ondondo et al. 2010; Zhang et al. 2014 ) and immunocompromised transplant patients (Bharat et al. 2015) . The unique physiology of these organisms results in high levels of intrinsic resistance to many clinically available antibiotics. For example, the absence of a peptidoglycan cell wall renders these organisms resistant to all betalactam and glycopeptide antibiotics. Only a limited number of antimicrobial classes are available for treatment including the macrolides, tetracyclines, fluoroquinolones and chloramphenicols. With respect to infection during pregnancy and among preterm neonates these options are further limited due to host toxicity issues. Tetracyclines
Letters in Applied Microbiology 64, 198--202 © 2016 The Society for Applied Microbiology are associated with deposition in growing teeth and bones, whereas systemic administration of chloramphenicol is associated with 'Grey baby' syndrome. Further complications arise as a result of isolates harbouring acquired resistance to the limited number of available antibiotics, with exception to chloramphenicol (Beeton et al. 2009b (Beeton et al. , 2015 . For these reasons, alternatives are urgently required.
Manuka honey has been shown to be a promising natural product with potent antimicrobial activity against pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa (Jenkins et al. 2011 (Jenkins et al. , 2012 . Unlike many traditional antibiotics which have a single site of action, honey has been suggested to have multiple antimicrobial components such as hydrogen peroxide, high levels of sugars and methylglyoxal (Maddocks and Jenkins 2013) . Due to the multifaceted antimicrobial nature of this product, it has been difficult to generate resistance in vitro (Cooper et al. 2010) .
Here, we present data demonstrating the first report of antimicrobial activity of Manuka honey against a cell wall-free bacterial pathogen. Additionally, we show no increase in susceptibility for clinical isolates characterized to have known mechanisms of antibiotic resistance, nor could resistance to honey be induced with repeated challenge of strains with concentrations of Manuka honey just below the MIC with classic in vitro step-wise training.
Results and discussion
A total of eight antibiotic susceptible Ureaplasma strains were initially examined for baseline susceptibility to Manuka honey using the modified broth microdilution method. For both Ureaplasma urealyticum and Ureaplasma parvum, the percentage of Manuka honey required to yield inhibition increased in relation to the increase in initial inoculum (from 7Á5% at 1 CCU to 18Á0% at 10 6 CCU for U. urealyticum and 4Á8% at 1 CCU to 15Á3% at 10 6 for U. parvum) ( for testing antimicrobials against Ureaplasma spp., the mean MIC for U. urealyticum was higher than that of U. parvum (13Á5 vs 12Á7 at 10 4 and 16Á7 vs 15Á8 at 10 5 ), but this difference was not statistically significant (P = 0Á49). Following the establishment of baseline MIC values for Manuka honey against both U. urealyticum and U. parvum, the activity was then assessed against a small representative collection of antibiotic-resistant strains. No increase in MIC was noted for any resistant strain at the recommended 10 4 or 10 5 CCU relative to the matched inoculum for each respective antibiotic susceptible species ( Table 2 ). The antibiotic susceptible strain HPA5 was serially passaged in subinhibitory concentrations of Manuka honey in an attempt to generate honey-resistant isolates. After 50 serial passages, no elevation in Manuka honey MIC was noted (data not shown).
The purpose of this study was to evaluate the antimicrobial activity of Manuka honey against a panel of clinical and laboratory strains of Ureaplasma spp. From this, we report the first example of antimicrobial activity of Manuka honey against a cell wall-free bacterial pathogen as well as retention of activity against clinically relevant antibiotic-resistant strains. Data available to date on the antimicrobial activity of Manuka honey have been generated in respect to typical bacterial pathogens such as U. urealyticum S. aureus and P. aeruginosa (Jenkins et al. 2011; Camplin and Maddocks 2014) . It has been suggested that one of the primary mechanisms of action of Manuka honey is targeting the cell-wall murein hydrolase therefore disrupting cellular division (Jenkins et al. 2011) . As a result of reductive evolution, ureaplasmas have lost the biosynthetic capabilities to synthesize the peptidoglycan cell wall. From the data presented here, we can speculate there are additional cellular targets other than the cell wall which leads to the antimicrobial activity, which reflects that previously suggested by Jenkins et al. (2014) . In addition, nonspecific effects as a result of osmotic imbalances may have contributed to the antimicrobial activity. The MIC values for both Ureaplasma spp. were lower than those reported for the ATCC 9027 strain of P. aeruginosa (25Á6% w/v), yet comparable to a clinical P. aeruginosa isolate (15Á3% w/v), (Camplin and Maddocks 2014 ) but were much higher than those previously reported for S. aureus <6% w/v (Jenkins et al. 2012 ). These subtle differences may be due to the sites of action upon the pathogen in question, such as the cell wall in S. aureus, or differences in the Unique Manuka Factor between batches of honey examined. When examining the MIC values between the Ureaplasma spp., we noted that U. urealyticum had consistently higher MIC values at the CLSI recommended inoculum of 10 4 to 10 5 when compared with U. parvum. Although this was not a statistically significant difference, this reflects the observations in species difference seen when examining the activity of antibiotics against these pathogens (Beeton et al. 2016) . Of clinical relevance was the observation that bacterial load played a substantial role in the MIC for both U. parvum and U. urealyticum. Low-grade infections would be treatable with much lower concentrations of honey, where as those with high titres, as seen clinically, would require much higher concentrations (Beeton et al. 2016) . Antibiotic-resistant strains have been reported for the major classes of antibiotics effective against ureaplasmas, most notably the macrolides, tetracyclines and fluoroquinolones (Beeton et al. 2009b (Beeton et al. , 2015 . For this reason, we examined the antimicrobial activity of honey against a panel of antibiotic-resistant clinical isolates. We observed retention of antimicrobial activity against these isolates suggesting no cross-resistance from either antibiotic resistance mechanism or the activity of honey. This is of significance in the case of preterm neonatal infections where macrolides are regarded the predominant antibiotic class of choice. Pereyre et al. (2007) have previously demonstrated the ease by which ureaplasmas can acquire point mutations resulting in the development of resistance following exposure to macrolides via step-wise resistance training (Pereyre et al. 2007) . Similarly, resistance to fluoroquinolones among Ureaplasma spp. results from the accumulation of mutations in the quinolone resistance determining regions (Beeton et al. 2009a) . The data presented here demonstrated that it was not possible to generate isolates with an increased honey MIC following a similar time frame in which macrolide resistance was generated (Pereyre et al. 2007) . This is likely due to the suggested multiple antimicrobial agents present with in Manuka honey (Maddocks and Jenkins 2013) . The inability to generate mutants is in line with previous reports for S. aureus and P. aeruginosa although a report by Camplin and Maddocks demonstrated an increase in MIC for P. aeruginosa isolates recovered from honey treated in vitro biofilms (Cooper et al. 2010; Camplin and Maddocks 2014) .
In summary, we have successfully demonstrated antimicrobial activity of Manuka honey against a bacterial pathogen with high levels of intrinsic and acquired antibiotic resistance in the absence of a cell wall. The mechanisms by which Manuka honey exerts antimicrobial activity in this atypical bacterial pathogen of increasing clinical significance warrants further investigation.
Materials and methods
A total of eight antibiotic susceptible Ureaplasma strains were examined. These comprised of four U. urealyticum including two clinical isolates (HPA99 and W11) and (Beeton et al. 2009b (Beeton et al. , 2015 . All Ureaplasma isolates were grown in Ureaplasma Selective Media purchased from Mycoplasma Experience (Surrey, UK). Susceptibility to Activon 100% Medical Grade Manuka honey, purchased from Advancis Medical (Nottinghamshire, UK), was determined using CLSI M43-A guidelines for antimicrobial susceptibility testing for human mycoplasmas. In brief, a dilution gradient of honey prepared in Ureaplasma Selective Media from 20% w/v to 0% w/v (2% increments) was prepared. One hundred and eighty micro litres of each dilution was then added to all wells with in columns of a 96-well microtitre plate. For example, 180 ll 20% w/v honey was added to wells A12-H12, 180 ll 18% w/v honey was added to wells A11-H11. Finally, 20 ll of a logarithmic phase culture of Ureaplasma was added to all the wells from A1 to A12; 1 : 10 dilutions from this were made across the plate from column 1 to column 8 as a means for determining the inhibitory activity of the Manuka honey at multiple concentrations of bacteria. Plates were sealed with an adhesive sealing film and incubated statically at 37°C until all colour change had ceased as determined visually (c. 48 h). Colour changing units (CCU) were defined by determining the final dilution in which colour change had occurred, orange to red due to increased pH as a result of urea hydrolysis; therefore, giving one CCU. From this, it was then possible to work back through the dilution gradient to determine the percentage of honey required to inhibit the growth of Ureaplasma at each CCU. The methodology as previously described by Pereyre et al., was used to select for honey-resistant mutants using the antibiotic susceptible strain HPA5 (Pereyre et al. 2007 ). Statistical analysis was performed using MINITAB ver. 17.0 to determine the statistical significance using a one-way ANOVA.
